Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cosyntropin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.73 |
| ▸ | MC4R | P32245 | 3/20 | 0.72 |
| ▸ | MC5R | P33032 | 2/20 | 0.72 |
| ▸ | MC3R | P41968 | 2/20 | 0.72 |
| ▸ | MC1R | Q01726 | 2/20 | 0.72 |
| ▸ | CTSL | P07711 | 3/20 | 0.64 |
| ▸ | CTSS | P25774 | 3/20 | 0.64 |
| ▸ | CTSK | P43235 | 3/20 | 0.64 |
| ▸ | CTSH | P09668 | 1/20 | 0.64 |
| ▸ | GLP1R | P43220 | 4/20 | 0.64 |
| ▸ | GCGR | P47871 | 3/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.60 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.59 |
| ▸ | NMBR | P28336 | 1/20 | 0.58 |
| ▸ | GRPR | P30550 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cosyntropin SCHEMBL16649167 | 1.00 | C5AR1 (0.73) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL31252906 | 1.00 | C5AR1 (0.73) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL25356191 | 1.00 | C5AR1 (0.73) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL29948667 | 0.99 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL29383133 | 0.99 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL27555834 | 0.99 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL720535 | 0.99 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL33366 | 0.99 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL522396 | 0.99 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL16649201 | 0.99 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616736-B2 | Method of diagnosis of adrenal insufficiency | SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST (GB) | 2026-05-05 | — | — | US | claimed |
| EP-3672642-B1 | METHOD OF DIAGNOSIS OF ADRENAL INSUFFICIENCY | SHEFFIELD CHILDRENS NHS FOUND TRUST (GB) | 2024-11-13 | — | — | EP | claimed |
| US-20200268851-A1 | METHOD OF DIAGNOSIS OF ADRENAL INSUFFICIENCY | SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST (GB) | 2020-08-27 | — | — | US | claimed |
| EP-3672642-A1 | METHOD OF DIAGNOSIS OF ADRENAL INSUFFICIENCY | Sheffield Children's NHS Foundation Trust (GB) | 2020-07-01 | — | — | EP | claimed |
| US-20060177444-A1 | Concomitant drug as therapeutic agent for inflammatory bowel disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-10 | — | — | US | claimed |
| EP-1607103-A1 | CONCOMITANT DRUG AS THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE | Eisai Co., Ltd. (JP) | 2005-12-21 | — | — | EP | claimed |
| US-20050025807-A1 | Cured porous calcium phosphate material and uses thereof | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY | 2005-02-03 | — | — | US | claimed |
| US-20030125528-A1 | Process for preparing schiff base adducts of amines with o-hydroxy aldehydes and compositions of matter based thereon | HAY BRUCE A (US) | 2003-07-03 | — | — | US | claimed |
| EP-1087989-A1 | IMPROVED PROCESS FOR PREPARING SCHIFF BASE ADDUCTS OF AMINES WITH O-HYDROXY ALDEHYDES AND COMPOSITIONS OF MATTER BASED THEREON | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| WO-2000000507-A1 | IMPROVED PROCESS FOR PREPARING SCHIFF BASE ADDUCTS OF AMINES WITH O-HYDROXY ALDEHYDES AND COMPOSITIONS OF MATTER BASED THEREON | PFIZER PRODUCTS INC. (US) | 2000-01-06 | — | — | WO | claimed |
| US-12616736-B2 | Method of diagnosis of adrenal insufficiency | SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST (GB) | 2026-05-05 | — | — | US | disclosed |
| US-12186432-B2 | Preparation method of sustained-release microparticles | AC PHARMACEUTICALS CO., LTD. (CN) | 2025-01-07 | — | — | US | disclosed |
| EP-3672642-B1 | METHOD OF DIAGNOSIS OF ADRENAL INSUFFICIENCY | SHEFFIELD CHILDRENS NHS FOUND TRUST (GB) | 2024-11-13 | — | — | EP | disclosed |
| EP-4389218-A2 | COMPOSITION FOR TREATING JOINT DISEASE AND KIT CONTAINING SAME | Seikagaku Corporation (JP) | 2024-06-26 | — | — | EP | disclosed |
| US-20240016745-A1 | TIMED-ELUTION MASKING PARTICLES AND ORAL PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2024-01-18 | — | — | US | disclosed |
| WO-2001062726-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2001-08-30 | — | — | WO | disclosed |
| EP-1087989-A1 | IMPROVED PROCESS FOR PREPARING SCHIFF BASE ADDUCTS OF AMINES WITH O-HYDROXY ALDEHYDES AND COMPOSITIONS OF MATTER BASED THEREON | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1082963-A1 | REMEDIES FOR JOINT DISEASES BOUND TO HYALURONIC ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-03-14 | — | — | EP | disclosed |
| WO-2000000507-A1 | IMPROVED PROCESS FOR PREPARING SCHIFF BASE ADDUCTS OF AMINES WITH O-HYDROXY ALDEHYDES AND COMPOSITIONS OF MATTER BASED THEREON | PFIZER PRODUCTS INC. (US) | 2000-01-06 | — | — | WO | disclosed |
| US-4421745-A | PEPTIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125528-A1 | Process for preparing schiff base adducts of amines with o-hydroxy aldehydes and compositions of matter based thereon | OGDH, ALDH7A1, AOX1 | C5AR1 3705/4885MC4R 4309/4885MC5R 4413/4885 |
| US-20060177444-A1 | Concomitant drug as therapeutic agent for inflammatory bowel disease | PPARG, PPARA, NR3C1 | C5AR1 710/4885MC4R 103/4885MC5R 63/4885 |
| US-12616736-B2 | Method of diagnosis of adrenal insufficiency | CRH, MC2R, NR3C2 | C5AR1 394/4885MC4R 271/4885MC5R 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.